ITOS · Iteos Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | $0 | $35.00M | $0 | - | $0 | $0 | $12.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $57.27M | $29.04M | - | $36.69M | $36.71M | $34.53M | - | $30.64M | $29.19M | $25.60M |
| SG&A | $10.18M | $10.98M | - | $12.11M | $12.46M | $12.70M | - | $12.64M | $13.44M | $11.93M |
| Total Operating Expenses | $83.79M | $40.02M | - | $48.80M | $49.17M | $47.23M | - | $43.28M | $42.62M | $37.52M |
| D&A | - | $324.0K | - | $300.0K | $300.0K | $304.0K | - | $200.0K | $200.0K | $222.0K |
| Operating Income | ($83.79M) | ($40.02M) | - | ($48.80M) | ($14.17M) | ($47.23M) | - | ($43.28M) | ($42.62M) | ($24.93M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $1.67M | $1.10M | - | $2.24M | $2.26M | $2.21M | - | ($1.18M) | $1.23M | $1.20M |
| Net Income | ($78.73M) | ($34.61M) | - | ($45.36M) | ($7.13M) | ($38.22M) | - | ($32.24M) | ($34.30M) | ($15.55M) |
| EPS - Basic | ($1.81) | ($0.80) | - | ($1.05) | ($0.18) | ($1.07) | - | ($0.90) | ($0.96) | ($0.44) |
| EPS - Diluted | ($1.81) | ($0.80) | - | ($1.05) | ($0.18) | ($1.07) | - | ($0.90) | ($0.96) | ($0.44) |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $207.82M | $156.54M | $142.13M | $123.74M | $251.10M | $146.65M | $251.18M | $204.13M | $216.21M | $225.36M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.25M | $14.00M | $8.50M | $7.15M | $11.05M | $5.53M | $11.29M | $3.42M | $5.23M | $5.69M |
| Current Assets | $528.99M | $537.04M | $509.54M | $544.88M | $626.61M | $480.39M | $550.65M | $619.13M | $614.55M | $615.40M |
| Total Assets | $623.08M | $658.87M | $686.98M | $723.08M | $751.84M | $629.77M | $667.59M | $677.64M | $703.75M | $728.35M |
| Current Liabilities | $70.27M | $38.00M | $40.36M | $36.81M | $34.67M | $35.56M | $40.01M | $28.22M | $30.02M | $26.36M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $129.28M | $95.45M | $96.68M | $91.39M | $87.97M | $88.57M | $92.36M | $79.38M | $80.22M | $76.08M |
| Stockholders' Equity | $493.80M | $563.42M | $590.29M | $631.69M | $663.87M | $541.20M | $575.23M | $598.26M | $623.53M | $652.26M |
| Retained Earnings | ($123.12M) | ($44.39M) | ($9.78M) | $33.93M | $79.29M | $86.42M | $124.63M | $155.18M | $187.42M | $221.72M |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($33.76M) | - | - | - | ($32.40M) | - | - | - | ($26.55M) |
| Investing Cash Flow | - | $47.69M | - | - | - | ($69.60M) | - | - | - | ($31.69M) |
| Financing Cash Flow | - | $32.0K | - | - | - | $22.0K | - | - | - | $578.0K |
| CapEx | - | $101.0K | - | - | - | $945.0K | - | - | - | $119.0K |
| Free Cash Flow | - | ($33.87M) | - | - | - | ($33.34M) | - | - | - | ($26.67M) |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -40.5% | - | - | - | - | -197.9% |
| EBITDA margin | - | - | - | - | -39.6% | - | - | - | - | -196.2% |
| Net margin | - | - | - | - | -20.4% | - | - | - | - | -123.5% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -211.8% |
| FCF / Net income | - | 0.98 | - | - | - | 0.87 | - | - | - | 1.72 |
| R&D / Revenue | - | - | - | - | 104.9% | - | - | - | - | 203.2% |
| SG&A / Revenue | - | - | - | - | 35.6% | - | - | - | - | 94.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.6% | -5.3% | - | -6.3% | -0.9% | -6.1% | - | -4.8% | -4.9% | -2.1% |
| Return on equity | -15.9% | -6.1% | - | -7.2% | -1.1% | -7.1% | - | -5.4% | -5.5% | -2.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.53 | 14.13 | 12.62 | 14.80 | 18.08 | 13.51 | 13.76 | 21.94 | 20.47 | 23.35 |
| Quick ratio | 7.53 | 14.13 | 12.62 | 14.80 | 18.08 | 13.51 | 13.76 | 21.94 | 20.47 | 23.35 |
| Cash ratio | 2.96 | 4.12 | 3.52 | 3.36 | 7.24 | 4.12 | 6.28 | 7.23 | 7.20 | 8.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.26 | 1.17 | 1.16 | 1.14 | 1.13 | 1.16 | 1.16 | 1.13 | 1.13 | 1.12 |
| Liabilities / Assets | 0.21 | 0.14 | 0.14 | 0.13 | 0.12 | 0.14 | 0.14 | 0.12 | 0.11 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | 0.00 | 0.05 | 0.00 | - | 0.00 | 0.00 | 0.02 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | - | - | - | -100.0% | - | -100.0% | -100.0% | -91.7% |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -491.5% | 15.3% | - | -12.7% | 66.8% | -89.5% | - | -184.6% | - | - |
| Net income growth (YoY) | -1004.5% | 9.4% | - | -40.7% | 79.2% | -145.7% | - | - | - | - |
| EPS growth (YoY) | -905.6% | 25.2% | - | -16.7% | 81.3% | -143.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -1.6% | - | - | - | -25.0% | - | - | - | -10.1% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -25.6% | 4.1% | 2.6% | 5.6% | 6.5% | -17.0% | -13.3% | -5.7% | -2.2% | 4.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Geographic
$35.00M totalBE$35.00M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing iTeos Therapeutics against the 5 most active filers in the same SIC group.